Here, standard-of-care therapy was predominantly recommended for newly diagnosed IDH-wild-type and IDH-mutant glioma, with the option of considering shorter courses of radiotherapy and avoidance of temozolomide in IDH-wild-type MGMT unmethylated tumors. The gene discussed is MGMT; the disease is central nervous system cancer.